166 related articles for article (PubMed ID: 38610031)
1. Pamiparib as consolidation treatment after concurrent chemoradiotherapy of limited-stage small cell lung cancer: a single-arm, open-label phase 2 trial.
Mao J; Ni J; Chu L; Chu X; Xu D; Yang X; Zhu Z
Radiat Oncol; 2024 Apr; 19(1):47. PubMed ID: 38610031
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale for a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Sugemalimab as Consolidation Therapy in Patients With Limited-Stage Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent or Sequential Chemoradiotherapy: The SURPASS Study.
Zhao S; Chen K; Shi X; Sun J; Fang W; Huang Y; Zhang L
Clin Lung Cancer; 2023 Nov; 24(7):e254-e258. PubMed ID: 37442748
[TBL] [Abstract][Full Text] [Related]
3. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
Senan S; Okamoto I; Lee GW; Chen Y; Niho S; Mak G; Yao W; Shire N; Jiang H; Cho BC
Clin Lung Cancer; 2020 Mar; 21(2):e84-e88. PubMed ID: 31948903
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: Phase 2 study results.
Ciardiello F; Bang YJ; Cervantes A; Dvorkin M; Lopez CD; Metges JP; Sánchez Ruiz A; Calvo M; Strickland AH; Kannourakis G; Muro K; Kawakami H; Wei J; Borg C; Zhu Z; Gupta N; Pelham RJ; Shen L
Cancer Med; 2023 Jun; 12(12):13145-13154. PubMed ID: 37260158
[TBL] [Abstract][Full Text] [Related]
5. Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y; Deng L; Wang J; Zhang T; Wang W; Wang X; Liu W; Wu Y; Lv J; Feng Q; Zhou Z; Wang J; Wang L; Wang Z; Bi N
Front Immunol; 2023; 14():1341584. PubMed ID: 38288117
[TBL] [Abstract][Full Text] [Related]
6. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
7. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
Faivre-Finn C; Falk S; Ashcroft L; Bewley M; Lorigan P; Wilson E; Groom N; Snee M; Fournel P; Cardenal F; Bezjak A; Blackhall F
BMJ Open; 2016 Jan; 6(1):e009849. PubMed ID: 26792218
[TBL] [Abstract][Full Text] [Related]
8. Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer.
Rimner A; Lai WV; Califano R; Jabbour SK; Rudin CM; Faivre-Finn C; Cho BC; Kato T; Yu J; Chafin W; Yu L; Zhao B; Byers L
Clin Lung Cancer; 2022 Jul; 23(5):e325-e329. PubMed ID: 35613997
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of fluzoparib combined with anlotinib in extensive stage small cell lung cancer after first-line platinum-based chemotherapy: a multi-center, single-arm prospective phase II clinical study (STAMP study).
Li D; Huang Z; Zhong J; Lin L; Zhang G; Zhuang W; Liu Z
BMC Cancer; 2023 Aug; 23(1):753. PubMed ID: 37580661
[TBL] [Abstract][Full Text] [Related]
10. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
Faivre-Finn C; Snee M; Ashcroft L; Appel W; Barlesi F; Bhatnagar A; Bezjak A; Cardenal F; Fournel P; Harden S; Le Pechoux C; McMenemin R; Mohammed N; O'Brien M; Pantarotto J; Surmont V; Van Meerbeeck JP; Woll PJ; Lorigan P; Blackhall F;
Lancet Oncol; 2017 Aug; 18(8):1116-1125. PubMed ID: 28642008
[TBL] [Abstract][Full Text] [Related]
11. A phase II, multicenter study of lazertinib as consolidation therapy in patients with locally advanced, unresectable, EGFR mutation-positive non-small cell lung cancer (stage III) who have not progressed following definitive, platinum-based, chemoradiation therapy (PLATINUM trial).
Choi J; Lee JE; Choi CM; Oh IJ; Lee KY; Jang TW; Lee SH; Kim EY; Park DW; Park SH; Lee SY
Thorac Cancer; 2022 Dec; 13(23):3431-3435. PubMed ID: 36259253
[TBL] [Abstract][Full Text] [Related]
12. GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy.
Zhou Q; Chen M; Wu G; Chang JH; Jiang O; Cui JW; Han G; Lin Q; Fang J; Chen GY; Wu YL
Transl Lung Cancer Res; 2020 Oct; 9(5):2008-2015. PubMed ID: 33209620
[TBL] [Abstract][Full Text] [Related]
13. Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
Salem A; Mistry H; Hatton M; Locke I; Monnet I; Blackhall F; Faivre-Finn C
JAMA Oncol; 2019 Mar; 5(3):e185335. PubMed ID: 30520977
[TBL] [Abstract][Full Text] [Related]
14. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
De Ruysscher D; Ramalingam S; Urbanic J; Gerber DE; Tan DSW; Cai J; Li A; Peters S
Clin Lung Cancer; 2022 May; 23(3):e264-e268. PubMed ID: 34489161
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
[TBL] [Abstract][Full Text] [Related]
17. Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
Nawrocki S; Sugajska A
BMC Cancer; 2020 Mar; 20(1):231. PubMed ID: 32188425
[TBL] [Abstract][Full Text] [Related]
18. Phase II Study of Consolidation Amrubicin After Concurrent Chemoradiotherapy in Patients With Limited-stage Small-cell Lung Cancer.
Yoshida H; Nagai H; Sakamori Y; Ozasa H; Nishimura T; Tomii K; Hirai T; Matsuo Y; Iizuka Y; Mizowaki T; Yoshimura K; Kim YH
In Vivo; 2020; 34(2):897-902. PubMed ID: 32111801
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study.
Mu S; Lin C; Skrzypczyk-Ostaszewicz A; Bulat I; Maglakelidze M; Skarbova V; Andreu-Vieyra C; Sahasranaman S
Cancer Chemother Pharmacol; 2021 Jul; 88(1):81-88. PubMed ID: 33772633
[TBL] [Abstract][Full Text] [Related]
20. Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial.
Chen J; Li C; Cao Y; Zhu L; Zhang B; You J; Hou H; Wang J; Yuan Z
BMC Cancer; 2022 Jul; 22(1):793. PubMed ID: 35854236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]